Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MED25-MAPK15

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MED25-MAPK15
	FusionPDB ID: 52733
	FusionGDB2.0 ID: 52733
		Hgene	Tgene
	Gene symbol	MED25	MAPK15
	Gene ID	81857	225689
	Gene name	mediator complex subunit 25	mitogen-activated protein kinase 15
	Synonyms	ACID1\|ARC92\|BVSYS\|CMT2B2\|P78\|PTOV2\|TCBAP0758	ERK7\|ERK8
	Cytomap	19q13.33	8q24.3
	Type of gene	protein-coding	protein-coding
	Description	mediator of RNA polymerase II transcription subunit 25ARC/mediator transcriptional coactivator subunitactivator interaction domain-containing protein 1activator-recruited cofactor 92 kDa componentmediator of RNA polymerase II transcription, subunit 25	mitogen-activated protein kinase 15ERK-7ERK-8MAP kinase 15MAPK 15extracellular regulated kinase 8 deltaextracellular signal-regulated kinase 7extracellular signal-regulated kinase 8
	Modification date	20200328	20200313
	UniProtAcc	Q71SY5 Main function of 5'-partner protein: FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Required for RARA/RXRA-mediated transcription. {ECO:0000269\|PubMed:14657022, ECO:0000269\|PubMed:14983011, ECO:0000269\|PubMed:17641689}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000312865, ENST00000538643,	ENST00000338033, ENST00000395107, ENST00000395108,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	10 X 6 X 6=360	1 X 1 X 1=1
	# samples	13	1
	** MAII score	log2(13/360*10)=-1.46948528330122 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(1/1*10)=3.32192809488736
Fusion gene context	PubMed: MED25 [Title/Abstract] AND MAPK15 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MED25 [Title/Abstract] AND MAPK15 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MED25(50335672)-MAPK15(144799864), # samples:3
Anticipated loss of major functional domain due to fusion event.	MED25-MAPK15 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MED25-MAPK15 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MED25-MAPK15 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MED25-MAPK15 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MED25	GO:0045944	positive regulation of transcription by RNA polymerase II	17641689
Tgene	MAPK15	GO:0006974	cellular response to DNA damage stimulus	19166846
Tgene	MAPK15	GO:0008284	positive regulation of cell proliferation	20638370
Tgene	MAPK15	GO:0010506	regulation of autophagy	22948227
Tgene	MAPK15	GO:0032212	positive regulation of telomere maintenance via telomerase	21531765
Tgene	MAPK15	GO:0046777	protein autophosphorylation	11875070
Tgene	MAPK15	GO:0051973	positive regulation of telomerase activity	21531765
Tgene	MAPK15	GO:0090494	dopamine uptake	28842414
Tgene	MAPK15	GO:1904355	positive regulation of telomere capping	21531765

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:50335672/chr8:144799864)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MED25 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across MAPK15 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000312865	MED25	chr19	50335672	+	ENST00000338033	MAPK15	chr8	144799864	+	3311	1535	53	3103	1016
ENST00000312865	MED25	chr19	50335672	+	ENST00000395107	MAPK15	chr8	144799864	+	2303	1535	53	2302	750
ENST00000312865	MED25	chr19	50335672	+	ENST00000395108	MAPK15	chr8	144799864	+	2234	1535	53	2233	727
ENST00000538643	MED25	chr19	50335672	+	ENST00000338033	MAPK15	chr8	144799864	+	2619	843	0	2411	803
ENST00000538643	MED25	chr19	50335672	+	ENST00000395107	MAPK15	chr8	144799864	+	1611	843	0	1610	536
ENST00000538643	MED25	chr19	50335672	+	ENST00000395108	MAPK15	chr8	144799864	+	1542	843	0	1541	513

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000312865	ENST00000338033	MED25	chr19	50335672	+	MAPK15	chr8	144799864	+	0.003732594	0.9962674
ENST00000312865	ENST00000395107	MED25	chr19	50335672	+	MAPK15	chr8	144799864	+	0.018404275	0.9815957
ENST00000312865	ENST00000395108	MED25	chr19	50335672	+	MAPK15	chr8	144799864	+	0.01450966	0.9854903
ENST00000538643	ENST00000338033	MED25	chr19	50335672	+	MAPK15	chr8	144799864	+	0.015556435	0.98444355
ENST00000538643	ENST00000395107	MED25	chr19	50335672	+	MAPK15	chr8	144799864	+	0.019031163	0.98096883
ENST00000538643	ENST00000395108	MED25	chr19	50335672	+	MAPK15	chr8	144799864	+	0.010451081	0.9895489

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MED25-MAPK15

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MED25	chr19	50335672	MAPK15	chr8	144799864	1535	260	PPAAPSGATLSAAPQQPLPPVPPQYQ
MED25	chr19	50335672	MAPK15	chr8	144799864	843	281	SLKGLYRIMGNGFAYGIVWKAVDRRT

Top

Potential FusionNeoAntigen Information of MED25-MAPK15 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MED25-MAPK15_50335672_144799864.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:01	RIMGNGFAY	0.9993	0.8943	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:25	RIMGNGFAY	0.9989	0.9009	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:02	RIMGNGFAY	0.9954	0.9182	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A80:01	RIMGNGFAY	0.9933	0.5237	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:17	RIMGNGFAY	0.9913	0.8497	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:05	APQQPLPPV	0.9901	0.6973	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:02	APQQPLPPV	0.9891	0.7552	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B39:06	YRIMGNGFA	0.9881	0.9099	5	14
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A03:12	RIMGNGFAY	0.9863	0.5317	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A03:25	RIMGNGFAY	0.986	0.5065	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:08	RIMGNGFAY	0.9849	0.9369	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A02:21	FAYGIVWKA	0.9842	0.5036	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:01	RIMGNGFAY	0.9713	0.9129	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A02:04	FAYGIVWKA	0.962	0.6861	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B53:01	NGFAYGIVW	0.9427	0.8048	10	19
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A32:13	RIMGNGFAY	0.9399	0.9803	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B15:16	LSAAPQQPL	0.9395	0.9789	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:02	APQQPLPPV	0.926	0.9404	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:03	RIMGNGFAY	0.9086	0.7535	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B56:01	APQQPLPPV	0.9042	0.9085	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A74:09	RIMGNGFAY	0.9011	0.661	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A74:11	RIMGNGFAY	0.9011	0.661	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A74:03	RIMGNGFAY	0.9011	0.661	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:01	APQQPLPPV	0.838	0.9306	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B55:01	APQQPLPPV	0.8257	0.7776	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:03	APQQPLPPV	0.7799	0.7749	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:02	APQQPLPPV	0.773	0.9791	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:04	APQQPLPPV	0.773	0.9791	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B82:01	APQQPLPPV	0.6265	0.7585	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B81:01	APQQPLPPV	0.5313	0.9233	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:05	YRIMGNGFAY	1	0.8345	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:02	YRIMGNGFAY	1	0.5386	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:04	YRIMGNGFAY	0.9999	0.7196	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A29:10	YRIMGNGFAY	0.9747	0.6292	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:02	YRIMGNGFAY	0.9479	0.9137	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:18	YRIMGNGFAY	0.9132	0.7199	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A80:01	YRIMGNGFAY	0.8991	0.595	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B46:01	YRIMGNGFAY	0.8984	0.5019	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A24:17	LYRIMGNGFAY	0.975	0.6388	4	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:19	SAAPQQPL	0.9999	0.9889	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:08	SAAPQQPL	0.9998	0.9475	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:04	SAAPQQPL	0.98	0.9916	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:13	SAAPQQPL	0.98	0.9916	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:03	SAAPQQPL	0.7927	0.9956	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:07	LSAAPQQPL	0.9994	0.9871	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:19	LSAAPQQPL	0.9991	0.9944	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:08	LSAAPQQPL	0.9991	0.9628	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B54:01	FAYGIVWKA	0.9988	0.5284	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C15:06	LSAAPQQPL	0.9984	0.9652	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:07	RIMGNGFAY	0.9975	0.7117	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:21	RIMGNGFAY	0.9952	0.8991	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:05	RIMGNGFAY	0.9915	0.8868	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B73:01	YRIMGNGFA	0.9914	0.7138	5	14
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C12:04	FAYGIVWKA	0.9902	0.9968	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C06:03	FAYGIVWKA	0.989	0.9967	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C01:17	LSAAPQQPL	0.9889	0.9882	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A03:01	RIMGNGFAY	0.986	0.5065	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:31	RIMGNGFAY	0.9767	0.8979	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:04	LSAAPQQPL	0.9742	0.9927	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:13	LSAAPQQPL	0.9742	0.9927	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:04	RIMGNGFAY	0.9741	0.8972	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C01:30	LSAAPQQPL	0.9731	0.9908	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:12	APQQPLPPV	0.971	0.7745	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B54:01	APQQPLPPV	0.9591	0.9636	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B78:01	FAYGIVWKA	0.939	0.8181	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C02:06	FAYGIVWKA	0.9021	0.9917	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:04	APQQPLPPV	0.8892	0.7345	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B78:01	APQQPLPPV	0.8843	0.983	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C02:06	LSAAPQQPL	0.8605	0.9874	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:03	LSAAPQQPL	0.8326	0.9964	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:08	APQQPLPPV	0.7994	0.8161	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:12	APQQPLPPV	0.773	0.9791	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C15:04	RIMGNGFAY	0.7453	0.9054	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B42:02	APQQPLPPV	0.7274	0.8553	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B56:04	APQQPLPPV	0.7062	0.9598	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B42:01	APQQPLPPV	0.652	0.8434	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C03:14	RIMGNGFAY	0.6229	0.9779	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B39:10	APQQPLPPV	0.4252	0.9898	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:14	YRIMGNGFAY	0.9999	0.8013	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:03	YRIMGNGFAY	0.9996	0.8437	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:95	YRIMGNGFAY	0.999	0.7549	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:27	YRIMGNGFAY	0.9987	0.9432	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:05	YRIMGNGFAY	0.9983	0.9512	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:19	YRIMGNGFAY	0.9965	0.7301	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:67	YRIMGNGFAY	0.994	0.939	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:80	YRIMGNGFAY	0.994	0.939	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:10	YRIMGNGFAY	0.9932	0.9488	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:46	YRIMGNGFAY	0.9926	0.8459	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A29:01	YRIMGNGFAY	0.9747	0.6292	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A29:02	YRIMGNGFAY	0.9747	0.6292	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:31	YRIMGNGFAY	0.9638	0.8822	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:21	YRIMGNGFAY	0.9397	0.8936	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C12:16	YRIMGNGFAY	0.9069	0.9813	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:03	SAAPQQPL	0.9999	0.9917	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:04	SAAPQQPL	0.9999	0.9917	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:17	SAAPQQPL	0.9996	0.9864	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:05	SAAPQQPL	0.9991	0.964	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:06	SAAPQQPL	0.9981	0.9937	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C16:01	SAAPQQPL	0.9676	0.9885	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:13	SAAPQQPL	0.8527	0.9353	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:01	SAAPQQPL	0.7927	0.9956	10	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:125	RIMGNGFAY	0.9993	0.8943	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:34	RIMGNGFAY	0.9993	0.8943	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:33	RIMGNGFAY	0.9993	0.8943	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:03	LSAAPQQPL	0.9993	0.9927	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:27	RIMGNGFAY	0.9993	0.8897	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:04	LSAAPQQPL	0.9993	0.9927	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:50	RIMGNGFAY	0.9993	0.9545	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:135	RIMGNGFAY	0.9992	0.8783	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:12	RIMGNGFAY	0.9991	0.8998	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:39	RIMGNGFAY	0.9989	0.8094	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:17	LSAAPQQPL	0.9988	0.9858	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:05	LSAAPQQPL	0.9987	0.9677	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C15:05	LSAAPQQPL	0.9983	0.9648	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:11	RIMGNGFAY	0.9981	0.8515	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:35	RIMGNGFAY	0.9979	0.8523	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:08	RIMGNGFAY	0.9978	0.8535	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:43	RIMGNGFAY	0.9964	0.8611	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:11	RIMGNGFAY	0.9929	0.8864	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:20	RIMGNGFAY	0.9918	0.9308	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C01:02	LSAAPQQPL	0.9912	0.9871	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:09	APQQPLPPV	0.99	0.74	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:22	APQQPLPPV	0.9891	0.7552	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:28	RIMGNGFAY	0.9875	0.9296	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C03:06	LSAAPQQPL	0.9867	0.9941	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C16:04	FAYGIVWKA	0.9864	0.9894	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A69:01	FAYGIVWKA	0.9858	0.691	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A68:02	FAYGIVWKA	0.9855	0.5722	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A02:06	FAYGIVWKA	0.9842	0.5036	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A32:01	RIMGNGFAY	0.9806	0.9798	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:20	RIMGNGFAY	0.9734	0.9371	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:23	RIMGNGFAY	0.9714	0.9082	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B35:77	RIMGNGFAY	0.9713	0.9129	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C16:01	LSAAPQQPL	0.9689	0.9897	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A02:03	FAYGIVWKA	0.9687	0.5778	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C12:03	FAYGIVWKA	0.9618	0.9906	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:22	APQQPLPPV	0.9529	0.8859	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B15:54	RIMGNGFAY	0.907	0.8663	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B53:02	NGFAYGIVW	0.9029	0.8342	10	19
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-A74:01	RIMGNGFAY	0.9011	0.661	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B78:02	FAYGIVWKA	0.8952	0.9504	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B55:02	APQQPLPPV	0.8805	0.912	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B78:02	APQQPLPPV	0.8766	0.9823	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B59:01	APQQPLPPV	0.8619	0.9646	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:13	APQQPLPPV	0.8395	0.936	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-C08:01	LSAAPQQPL	0.8326	0.9964	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:09	APQQPLPPV	0.8319	0.9351	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:14	APQQPLPPV	0.8267	0.8648	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:13	LSAAPQQPL	0.8233	0.9489	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B55:04	APQQPLPPV	0.8192	0.8672	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B56:05	APQQPLPPV	0.8054	0.9155	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:26	APQQPLPPV	0.7969	0.6976	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:09	APQQPLPPV	0.773	0.9791	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:05	APQQPLPPV	0.7723	0.7083	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:21	APQQPLPPV	0.7635	0.9415	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B35:13	APQQPLPPV	0.7605	0.7788	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B51:29	APQQPLPPV	0.7571	0.8738	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C15:09	RIMGNGFAY	0.7453	0.9054	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B48:02	RIMGNGFAY	0.7386	0.9219	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B56:02	APQQPLPPV	0.7062	0.9598	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C12:02	FAYGIVWKA	0.6586	0.9813	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C03:02	RIMGNGFAY	0.6438	0.9761	6	15
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B82:02	APQQPLPPV	0.6265	0.7585	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C02:02	FAYGIVWKA	0.6211	0.9925	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C02:10	FAYGIVWKA	0.6211	0.9925	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B67:01	APQQPLPPV	0.5436	0.9931	12	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	HLA-B07:13	LSAAPQQPL	0.5213	0.916	9	18
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:08	YRIMGNGFAY	1	0.7208	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-B27:10	YRIMGNGFAY	0.9999	0.855	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:01	YRIMGNGFAY	0.9991	0.6184	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:17	YRIMGNGFAY	0.9975	0.9705	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:02	YRIMGNGFAY	0.994	0.939	5	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	HLA-C07:22	YRIMGNGFAY	0.9855	0.7469	5	15

Top

Potential FusionNeoAntigen Information of MED25-MAPK15 in HLA II

MED25-MAPK15_50335672_144799864.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0401	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0401	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0407	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0407	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0419	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0419	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0419	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0431	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0431	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0433	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0433	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0435	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0435	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0438	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0438	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0443	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0443	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0443	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0447	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0447	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0447	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0454	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0454	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0461	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0461	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0461	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0463	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0463	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0475	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0475	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0476	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0476	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0480	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0480	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0482	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0482	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0801	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0801	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0803	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0803	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0805	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0805	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0808	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0808	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0811	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0811	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0814	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0814	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0816	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0816	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0818	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0818	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0823	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0823	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0826	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0826	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0827	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0827	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0829	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0829	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0829	GNGFAYGIVWKAVDR	9	24
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0833	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0833	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0835	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0835	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0836	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0836	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0837	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0837	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0838	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0838	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0839	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0839	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0840	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0840	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0901	GATLSAAPQQPLPPV	6	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0901	SGATLSAAPQQPLPP	5	20
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0901	PSGATLSAAPQQPLP	4	19
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-0902	GNGFAYGIVWKAVDR	9	24
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0904	GATLSAAPQQPLPPV	6	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0904	SGATLSAAPQQPLPP	5	20
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0904	PSGATLSAAPQQPLP	4	19
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0905	GATLSAAPQQPLPPV	6	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0905	SGATLSAAPQQPLPP	5	20
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0906	GATLSAAPQQPLPPV	6	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0906	SGATLSAAPQQPLPP	5	20
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0906	PSGATLSAAPQQPLP	4	19
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0906	ATLSAAPQQPLPPVP	7	22
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0907	GATLSAAPQQPLPPV	6	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0907	SGATLSAAPQQPLPP	5	20
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0909	GATLSAAPQQPLPPV	6	21
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0909	SGATLSAAPQQPLPP	5	20
MED25-MAPK15	chr19	50335672	chr8	144799864	1535	DRB1-0909	PSGATLSAAPQQPLP	4	19
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1130	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1130	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1303	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1303	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-13101	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-13101	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1310	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1310	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1312	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1312	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1313	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1313	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1321	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1321	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1330	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1330	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1330	GNGFAYGIVWKAVDR	9	24
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1349	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1349	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1355	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1355	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1366	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1366	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1388	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1388	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1390	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1390	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1395	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1395	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1413	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1422	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1422	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1425	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1425	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1446	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1453	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1453	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1463	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1463	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1469	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1469	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1485	GFAYGIVWKAVDRRT	11	26
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1485	NGFAYGIVWKAVDRR	10	25
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1515	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1515	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1527	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1527	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1534	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1534	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1601	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1601	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1601	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1602	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1602	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1603	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1603	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1603	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1604	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1604	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1605	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1605	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1607	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1607	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1608	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1608	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1608	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1609	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1609	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1609	SLKGLYRIMGNGFAY	0	15
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1610	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1610	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1611	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1611	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1612	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1612	KGLYRIMGNGFAYGI	2	17
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1614	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1616	LKGLYRIMGNGFAYG	1	16
MED25-MAPK15	chr19	50335672	chr8	144799864	843	DRB1-1616	KGLYRIMGNGFAYGI	2	17

Top

Fusion breakpoint peptide structures of MED25-MAPK15

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2676	GATLSAAPQQPLPP	MED25	MAPK15	chr19	50335672	chr8	144799864	1535

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7940	RIMGNGFAYGIVWK	MED25	MAPK15	chr19	50335672	chr8	144799864	843

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MED25-MAPK15

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	2676	GATLSAAPQQPLPP	-6.62904	-6.74084
HLA-B14:02	3BVN	2676	GATLSAAPQQPLPP	-4.47112	-5.51422
HLA-B52:01	3W39	2676	GATLSAAPQQPLPP	-6.67729	-6.78909
HLA-B52:01	3W39	2676	GATLSAAPQQPLPP	-3.57043	-4.61353
HLA-A11:01	4UQ2	2676	GATLSAAPQQPLPP	-8.27675	-8.38855
HLA-A24:02	5HGA	2676	GATLSAAPQQPLPP	-6.47973	-6.59153
HLA-A24:02	5HGA	2676	GATLSAAPQQPLPP	-5.29795	-6.34105
HLA-B44:05	3DX8	2676	GATLSAAPQQPLPP	-6.59186	-7.63496
HLA-B44:05	3DX8	2676	GATLSAAPQQPLPP	-4.74709	-4.85889
HLA-A02:01	6TDR	2676	GATLSAAPQQPLPP	-4.32034	-5.36344
HLA-B14:02	3BVN	7940	RIMGNGFAYGIVWK	-7.9962	-8.1096
HLA-B14:02	3BVN	7940	RIMGNGFAYGIVWK	-5.70842	-6.74372
HLA-B52:01	3W39	7940	RIMGNGFAYGIVWK	-6.83737	-6.95077
HLA-B52:01	3W39	7940	RIMGNGFAYGIVWK	-4.4836	-5.5189
HLA-A11:01	4UQ2	7940	RIMGNGFAYGIVWK	-10.0067	-10.1201
HLA-A11:01	4UQ2	7940	RIMGNGFAYGIVWK	-9.03915	-10.0745
HLA-A24:02	5HGA	7940	RIMGNGFAYGIVWK	-6.56204	-6.67544
HLA-A24:02	5HGA	7940	RIMGNGFAYGIVWK	-5.42271	-6.45801
HLA-B44:05	3DX8	7940	RIMGNGFAYGIVWK	-7.85648	-8.89178
HLA-B44:05	3DX8	7940	RIMGNGFAYGIVWK	-5.3978	-5.5112
HLA-A02:01	6TDR	7940	RIMGNGFAYGIVWK	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of MED25-MAPK15

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MED25-MAPK15	chr19	50335672	chr8	144799864	10	18	SAAPQQPL	AACGGCTTCGCCTATGGCATTGTG
MED25-MAPK15	chr19	50335672	chr8	144799864	10	19	NGFAYGIVW	AACGGCTTCGCCTATGGCATTGTGTGG
MED25-MAPK15	chr19	50335672	chr8	144799864	12	21	APQQPLPPV	TTCGCCTATGGCATTGTGTGGAAGGCA
MED25-MAPK15	chr19	50335672	chr8	144799864	12	21	FAYGIVWKA	TTCGCCTATGGCATTGTGTGGAAGGCA
MED25-MAPK15	chr19	50335672	chr8	144799864	4	15	LYRIMGNGFAY	CTCTACCGCATCATGGGCAACGGCTTCGCCTAT
MED25-MAPK15	chr19	50335672	chr8	144799864	5	14	YRIMGNGFA	TACCGCATCATGGGCAACGGCTTCGCC
MED25-MAPK15	chr19	50335672	chr8	144799864	5	15	YRIMGNGFAY	TACCGCATCATGGGCAACGGCTTCGCCTAT
MED25-MAPK15	chr19	50335672	chr8	144799864	6	15	RIMGNGFAY	CGCATCATGGGCAACGGCTTCGCCTAT
MED25-MAPK15	chr19	50335672	chr8	144799864	9	18	LSAAPQQPL	GGCAACGGCTTCGCCTATGGCATTGTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
MED25-MAPK15	chr19	50335672	chr8	144799864	0	15	SLKGLYRIMGNGFAY	TCTCTCAAAGGCCTCTACCGCATCATGGGCAACGGCTTCGCCTAT
MED25-MAPK15	chr19	50335672	chr8	144799864	1	16	LKGLYRIMGNGFAYG	CTCAAAGGCCTCTACCGCATCATGGGCAACGGCTTCGCCTATGGC
MED25-MAPK15	chr19	50335672	chr8	144799864	10	25	NGFAYGIVWKAVDRR	AACGGCTTCGCCTATGGCATTGTGTGGAAGGCAGTGGACCGGAGG
MED25-MAPK15	chr19	50335672	chr8	144799864	11	26	GFAYGIVWKAVDRRT	GGCTTCGCCTATGGCATTGTGTGGAAGGCAGTGGACCGGAGGACT
MED25-MAPK15	chr19	50335672	chr8	144799864	2	17	KGLYRIMGNGFAYGI	AAAGGCCTCTACCGCATCATGGGCAACGGCTTCGCCTATGGCATT
MED25-MAPK15	chr19	50335672	chr8	144799864	4	19	PSGATLSAAPQQPLP	CTCTACCGCATCATGGGCAACGGCTTCGCCTATGGCATTGTGTGG
MED25-MAPK15	chr19	50335672	chr8	144799864	5	20	SGATLSAAPQQPLPP	TACCGCATCATGGGCAACGGCTTCGCCTATGGCATTGTGTGGAAG
MED25-MAPK15	chr19	50335672	chr8	144799864	6	21	GATLSAAPQQPLPPV	CGCATCATGGGCAACGGCTTCGCCTATGGCATTGTGTGGAAGGCA
MED25-MAPK15	chr19	50335672	chr8	144799864	7	22	ATLSAAPQQPLPPVP	ATCATGGGCAACGGCTTCGCCTATGGCATTGTGTGGAAGGCAGTG
MED25-MAPK15	chr19	50335672	chr8	144799864	9	24	GNGFAYGIVWKAVDR	GGCAACGGCTTCGCCTATGGCATTGTGTGGAAGGCAGTGGACCGG

Top

Information of the samples that have these potential fusion neoantigens of MED25-MAPK15

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	MED25-MAPK15	chr19	50335672	ENST00000312865	chr8	144799864	ENST00000338033	TCGA-OL-A66I-01A
BRCA	MED25-MAPK15	chr19	50335672	ENST00000538643	chr8	144799864	ENST00000338033	TCGA-OL-A66I-01A

Top

Potential target of CAR-T therapy development for MED25-MAPK15

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MED25-MAPK15

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MED25-MAPK15

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)